Wizemann, Theresa, Robinson, Sally, Giffin, Robert. "Appendix B: Speaker Biographies." Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies: Workshop Summary. Washington, DC: The National Academies Press, 2008.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies - Workshop Summary
governmental advisory committees on medical research and services, and is liaison to the Secretary’s Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children and the National Advisory Council for National Human Genome Research Institute (NHGRI), NIH. She is on the steering committees of the Genetic Association Information Network of NHGRI, the Collaboration, Education and Test Translation (CETT) program, the Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Stakeholders Group, and the Google Health Advisory Board. She serves on the boards of the Biotechnology Institute, DNA Direct, the National Coalition of Health Professional Education in Genetics, and the Coalition for 21st Century Medicine. She is Chair of the Coalition for Genetic Fairness, which was instrumental in the passage of the Genetic Information Nondiscrimination Act. She is a member of the IOM Roundtable on Translating Genomic-Based Research for Health. She is also Chair of the Social Issues Committee of the American Society of Human Genetics. In 2005, she received an honorary doctorate from Iona College for her work in community engagement and haplotype mapping, and in 2007 she received the first Patient Service Award from the University of North Carolina Institute for Pharmacogenomics and Individualized Therapy.
Diana R. Wetmore, Ph.D., is Vice President of Alliance Management for Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT). Since joining CFFT in 2003, she has managed the strategic planning process for the CF Foundation–supported therapeutics pipeline, identified and launched multiple new discovery and development projects with industry collaborators, and provided ongoing project management support for CFFTs discovery and development projects. Some of the projects directed by Dr. Wetmore include the CFFT discovery collaborations with EPIX Pharmaceuticals, SGX Pharmaceuticals, and FoldRx, and development collaborations with PTC Therapeutics, Transave, and Mpex. Additional projects managed in her group include the CFFT Specimen Bank with ProMedDx, the MetaMiner CF informatics platform with GeneGo, and the CF Biomarker validation initiative. As a business-oriented scientist, Dr. Wetmore has had a successful career managing complex multidisciplinary drug discovery projects and teams. She obtained her Ph.D. in biochemistry at the University of Calgary in Canada, where her interest was in studying the contributions of ligand binding to protein folding and stability. Prior to joining CFFT, she held positions in the pharmaceutical and biotechnology industries. At Dupont Merck Pharmaceuticals (now Bristol Myers Squibb), she was part of the crystallography group and studied protein–protein and protein–ligand interactions using calorimetric methods. During her 5-year tenure at Scriptgen Pharmaceuticals, now Anadys, she led the bifunctional drug design group before becoming Senior Director of R&D Project Management. At Geneprot, Inc., she served as Chief Technical Officer